Eisai’s, DSP’s Growth Scenario Becoming More Realistic: Tachibana Securities

A recent report on the pharmaceutical industry issued by Tachibana Securities focuses on Eisai and Dainippon Sumitomo Pharma (DSP). “Their growth scenario based on new drugs which are expected to become their cash cows in the future is becoming realistic,”...read more